irinotecan liposomal

Irinotecan hydrochloride liposome injection combined with oxaliplatin and 5-FU/LV for the treatment of liver metastasis from advanced pancreatic cancer: A multicenter, open-access, Phase II exploratory study (ChiCTR2500109550)

Phase I/II exploratory study of irinotecan liposome + capecitabine + oxaliplatin in the treatment of patients with borderline resectable/locally advanced pancreatic cancer (ChiCTR2500107156)

A prospective, single-arm phase II clinical study of liposomal irinotecan in combination with interleukin-2 and sintilimab in the second-line treatment of patients with advanced gastric cancer (ChiCTR2500106811)

Phase II Study of Irinotecan Liposomes Combined With 5-FU/LV+ Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer (ChiCTR2500104331)

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma (clinicaltrials.gov)

Irinotecan Liposomes with Capecitabine and Bevacizumab for the Elderly Colorectal Cancer Patients Failed to Oxaliplatin-based Regimen: The LIVE Study (ChiCTR2500100308)

Irinotecan liposome combined with capecitabine + sintilimab +/- bevacizumab as first-line therapy for patients with RAS mutation and MSS-type metastatic colorectal cancer (ChiCTR2500097870)

The efficacy and safety research of irinotecan liposome injection combined with 5-FU/LV for HAIC+- Sindillizumab and Bevacizumab in the treatment of unresectable advanced biliary tract cancer (ChiCTR2400092319)

Single-arm, multicenter, exploratory clinical study of irinotecan liposomes combined with oxaliplatin and 5-Fu/Lv in second-line treatment of locally advanced or metastatic pancreatic cancer (ChiCTR2400094119)

A Study on Irinotecan Liposome Injection for Neoadjuvant Treatment of Colorectal Cancer Patients (ChiCTR2400092630)

Phase I clinical study of irinotecan liposome combined with furoquininib in the third-line and beyond patients with advanced colorectal cancer (ChiCTR2400092084)

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer (clinicaltrials.gov)